With high rates of efficacy and safety failures in the clinic, drug developers need to ensure that improved prediction of clinical effect is achieved earlier in the drug development pipeline.
But what in vitro models should you select? How do you achieve validation of a new assay or model? What candidates do you go after and screen? How have different tools performed so far and what new technologies are being developed?
These are just some of the questions that leading drug developers Eli Lilly, Merck Serono, AstraZeneca, UCB and Celgene amongst others are asking themselves. The 2nd Predictive In Vitro Models Summit will bring together a great mix of industry leaders from pharma/biotech companies/academia to discuss how you can increase your pre-clinical predictive capability.
http://invitro-models.com/
But what in vitro models should you select? How do you achieve validation of a new assay or model? What candidates do you go after and screen? How have different tools performed so far and what new technologies are being developed?
These are just some of the questions that leading drug developers Eli Lilly, Merck Serono, AstraZeneca, UCB and Celgene amongst others are asking themselves. The 2nd Predictive In Vitro Models Summit will bring together a great mix of industry leaders from pharma/biotech companies/academia to discuss how you can increase your pre-clinical predictive capability.
http://invitro-models.com/
